Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acura To Launch Nexafed PSE Despite Limits Of Extraction Resistance

This article was originally published in The Tan Sheet

Executive Summary

The spread of “one-pot” meth manufacturing will not deter Acura Pharmaceuticals from launching its OTC extraction-resistant PSE product, Nexafed. Making PSE products available in an extraction-resistant delivery formulation could offer an alternative to moving all dosages of the ingredient to the Rx class.

Advertisement

Related Content

Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests
Tamper-Resistant Pseudoephedrine Sparks Pharmacies’ Interest
Tamper-Resistant Pseudoephedrine Sparks Pharmacies’ Interest
Pisgah Labs’ PSE Extraction-Resistance Work Undeterred By Claims Outlook
In Brief
State Officials Urging Rx Pseudoephedrine Face Strong Lobby
In Brief
Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel